Whole Exome Sequencing Market size was over USD 4.62 billion in 2024 and is anticipated to cross USD 83.17 billion by 2037, witnessing more than 24.9% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of whole exome sequencing is estimated at USD 5.54 billion.. The growth of the market can be attributed to growing number of people having genetic mutation. A mutation, often known as a change in a gene, is the cause of more than about 9000 human diseases. About 9 out of every 1000 persons are impacted. According to this, between approximately 60 million and 80 million people worldwide are afflicted by one of these illnesses. Hence, the demand for whole exome sequencing is estimated to increase. Exome sequencing has been proven to be able to identify genetic variants linked to developmental and birth abnormalities. Hence, exome sequencing may allow patients who have a family history of disease or are looking for a diagnosis to explain their symptoms to forego unnecessary diagnostic procedures.
Moreover, the market is also being driven by rising R&D in the fields of genomics and next-generation sequencing. For instance, in May 2022 NanoString Technologies, Inc. released a cloud-based process that enhances the spatial data analysis experience for users of the GeoMx Digital Spatial Profiler and Illumina NextSeq 1000 and NextSeq 2000 sequencing equipment. With the help of this integrated, push-button run planning tool, the geographical analysis of whole transcriptomes and proteome analytes has been made simpler. Hence, the whole exome sequencing market is anticipated to be driven by such advancements. Also, the government spending on R&D for whole exome sequencing is also growing which is also estimated to boost the growth of the market over the forecast period.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
24.9% |
|
Base Year Market Size (2024) |
USD 4.62 billion |
|
Forecast Year Market Size (2037) |
USD 83.17 billion |
|
Regional Scope |
|
Application (Diagnostics, Drug Discovery & Development, Personalized Medicine, Agriculture & Animal Research)
The global whole exome sequencing market is segmented and analyzed for demand and supply by application into diagnostics, drug discovery & development, personalized medicine, and agriculture & animal research. Out of which, the personalized medicine segment is anticipated to garner the highest revenue by the end of 2037. The growth of the segment can be attributed to growing prevalence of multiple cancer forms. Since, more people than ever before are receiving their initial cancer diagnosis later in life, second cancers are becoming more prevalent. One in about five individuals with a cancer diagnosis have already experienced another type of malignancy in America. Hence, a greater focus is being placed on personalized medicine. Moreover, this is also driven by a fundamental change from the "one size fits all" model for treating individuals with disorders or a propensity for diseases, and towards one that embraces novel approaches, including personalized target medicines, to get the greatest results. In order to profit from personalized treatment, a number of national and international genome initiatives have been launched. In contrast to whole genome sequencing, exome and targeted sequencing offer a compromise between cost and utility.
Product (Systems, Kits, Services)
The global whole exome sequencing market is also segmented and analyzed for demand and supply by product into systems, kits, and services. Amongst which, services segment is anticipated to have a significant growth over the forecast period. Researchers could devote more time to their work rather than tedious analytical tasks as a result of the sophisticated bioinformatics visualization capabilities given by Next-Generation Sequencing (NGS) and data analysis services. These sequence analysis services provide a variety of services, including experimental planning, library construction from a variety of samples, and downstream DNA sequence analysis. The complexity of a number of bioinformatics-related problems has been reduced for scientists and researchers owing to these services, which have also decreased the amount of time and money required for sequencing and data management. Using whole exome sequencing, which focuses on the most crucial portion of the genome, enables researchers to more effectively utilize sequencing and analytical resources.
Our in-depth analysis of the global whole exome sequencing market includes the following segments:
|
By Product |
|
|
By Technology |
|
|
By Application |
|
|
By End-User
|
|
North American Market Forecast
The whole exome sequencing market share of whole exome sequencing in North America, amongst the market in all the other regions, is projected to have the highest growth, backed by growing prevalence of hereditary and chronic disease, along with surge in demand for targeted and precision medicine. About half of all Americans (around 45%, or 133 million) experienced at least one chronic illness in 2018, and the number is rising. Chronic illnesses are a particular category of silent illness that, if not treated in a timely manner, could harm individuals irreversibly. Hence, the market for whole exome sequencing in North America is growing. Moreover, next-generation sequencing (NGS) is becoming a potent tool for delivering a deeper and more precise insight at the molecular underpinnings of individual tumors and specific receptors as genomics-focused pharmacology continues to play a greater role in the treatment of various chronic diseases, particularly cancer in North America.
Europe Market Forecast
The European whole exome sequencing market is estimated to be the second largest, to have the highest growth over the forecast period. The Human Immunodeficiency Virus (HIV) and rising cancer rates have both had a big positive impact on the European market. The increased use of genetics in medicine has also significantly impacted the next-generation sequencing market in Europe's future expansion. Genome editing, gene synthesis, and next-generation sequencing are just a few of the technologies employed in genomics. Given the consistently falling cost of sequencing and strategic alliances between top corporations and premier research universities, the Germany market accounted for the greatest revenue share. A further factor in this region's market revenue increase is the rising prevalence of genetic diseases.
APAC Market Statistics
Additionally, the whole exome sequencing market in Asia Pacific region is estimated to have the significant growth over the forecast period. The growth of the market in this region can be attributed to growing genetic abnormalities in this region. However, given the significant socioeconomic differences in the region and the paucity of research, knowledge, and health policies for those with rare diseases, managing rare diseases is particularly difficult in Asia and the Pacific. The area also struggles with a lack of medical knowledge and momentum when it comes to recognizing and meeting patients' unmet needs. Most crucially, these shortcomings are made worse by the paternalistic health systems in the area, where patients' opinions are rarely valued or heard. Hence, government are taking initiatives in order to spread awareness among people and also investing highly on research & development of exome sequencing.
The first blood virological profile of the Chinese population was created in October 2022 by BGI Group, Ruijin Hospital, and Shanghai Jiao Tong University Institute of Translational Medicine using BGI's DNBSEQ sequencing platform. This analysis involved a thorough examination of non-human genetic sequences in the whole genome sequencing (WGS) data of about 10,584 individuals from the China Metabolic Analysis Program (ChinaMAP). The findings, which were published in the journal Cell Discovery, serve as a resource for viral infection epidemiology and prevention.
The SEQuoia RiboDepletion Kit, which increases test efficiency by removing pointless ribosomal RNA (rRNA) fragments from an RNA-Seq library, has been introduced by Bio-Rad Laboratories, Inc., a world leader in life science research and clinical diagnostic products.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?